Es wurden 41 Aussendungen gefunden
  • Eli Lilly and Company
Lilly veröffentlicht Aktualisierung über Tätigkeiten im Corporate-Responsibility-Bereich

(PRN) - - Unternehmen meldet Fortschritte bei zahlreichen ökonomischen, ökologischen und sozialen Leistungskennzahlen

  • 03.12.2012, 13:03:36
  • /
  • OTS0167 OTW0167
  • Eli Lilly and Company
Lilly Global gibt Mitarbeitern mehr Möglichkeiten zu gemeinnütziger Arbeit

Indianapolis (ots/PRNewswire) -

  • 26.07.2011, 01:59:03
  • /
  • OTS0002 OTW0002
  • Eli Lilly and Company
Lilly CEO Says Industry, Public Policy Must Pave Way For Innovation

London (ots/PRNewswire) - A new approach to research, along with public policies that support medical innovation, will help biopharmaceutical companies address stubborn diseases with potentially devastating personal...

  • 10.02.2011, 10:17:33
  • /
  • OTE0005
  • Eli Lilly and Company
Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials

Indianapolis, August 17, 2010 (ots/PRNewswire) - Eli Lilly and Company will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary...

  • 17.08.2010, 14:01:36
  • /
  • OTE0006
  • Eli Lilly and Company
Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor

Indianapolis, November 13 (ots/PRNewswire) -

  • 13.11.2009, 15:11:41
  • /
  • OTE0006
  • Eli Lilly and Company
New Data Show Duloxetine Maintained Pain Reduction for More Than Six Months in Patients With Diabetic Peripheral Neuropathic Pain

Indianapolis (ots/PRNewswire) -

  • 19.08.2008, 16:20:35
  • /
  • OTE0012
  • Eli Lilly and Company
Phase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimer's Disease

Chicago (ots/PRNewswire) -

  • 30.07.2008, 22:22:37
  • /
  • OTE0007
  • Eli Lilly and Company
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease

Indianapolis (ots/PRNewswire) -

  • 31.03.2008, 10:04:09
  • /
  • OTE0008
  • Eli Lilly and Company
FORSTEO(R) erhält positive Einschätzung des Europäischen Ausschusses für Humanarzneimittel (CHMP) zur Behandlung von glukokortikoidinduzierter Osteoporose

Indianapolis (ots/PRNewswire) -

  • 23.02.2008, 00:02:04
  • /
  • OTS0001 OTW0001
  • Eli Lilly and Company
Global 'Inspired by Diabetes' Creative Expression Competition Deadline Extended Until March 31, 2008

Indianapolis (ots/PRNewswire) -

  • 05.02.2008, 22:59:08
  • /
  • OTE0011